EGFR suppression and drug-induced potentiation are widespread features of oncogenic RTK fusions
Yuzhi Gao, David Gonzalez-Martinez, Sofia Wissert, Hana Bader, Nidhi Sahni, Anh Le, Robert Charles Doebele, Lukasz J. Bugaj
The paper shows that RTK fusions suppress EGFR and sequester Grb2, and targeted therapies reverse this suppression, enhancing EGFR signaling and drug response.
bioRxiv · Nov 19, 2025 · PreprintCancer Biology